Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Rheumatology
•
Osteoporosis
•
Denosumab
•
Bisphosphonate
•
Endocrinology
In a patient with history of atypical femoral fracture while on denosumab how do you sequence further treatment options?
Related Questions
What is your approach to a patient on long-term denosumab who now requires multiple invasive dental procedures?
How would you approach treatment of glucocorticoid induced osteoporosis in a patient 10 years post renal transplant, egfr > or =35, on chronic prednisone therapy who has completed 10 years of bisphosphonate therapy and whose DEXA continues to be T-score <~2.5?
For postmenopausal osteoporosis, would you give denosumab after a course of teriparatide and romosozumab to women who had an atypical femoral fracture while on bisphosphonate therapy a few years earlier?
Would you use romosozumab in a patient with a cardiovascular event more than 2 years prior?
How would you weight parental atypical femoral fracture that occurred after 15 years of bisphosphonate use when deciding on osteoporosis therapy?
How do you reduce the risk of contralateral fracture in a patient with atypical femur fracture from prolonged bisphosphonate use?
How do you approach significant change in BMD in premenopausal patient on tamoxifen?
What treatment would you consider for severe osteoporosis in a patient with multiple fractures, AVN of jaw from denosumab, history of stroke and who has completed a PTH analog?
Is history of radiation an absolute contraindication to using parathyroid hormone (PTH) analogues?
How do you approach long term management of glucocorticoid-induced osteoporosis in patients who develop osteonecrosis of the jaw on antiresorptive agent?
